Zevra Therapeutics (ZVRA) News
NASDAQ: ZVRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
8.76-0.31 (-3.42%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ZVRA news summary
We found 10 recent headlines mentioning Zevra Therapeutics (ZVRA): 1 in the past week and 8 in the past 30 days, most often from Nasdaq, GlobeNewswire, Seeking Alpha. For price context, ZVRA is down 3.42% at $8.76. The most recent story, "Zevra Therapeutics to Present at the Piper Sandler Annual Healthcare Conference", was published by GlobeNewswire on Nov 18, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Zevra Therapeutics headlines
- Zevra Therapeutics to Present at the Piper Sandler Annual Healthcare ConferenceBOSTON, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company committed to redefining what's possible in bringing…GlobeNewswire
- Zevra Therapeutics Announces Final CHMP Opinion on Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European UnionEuropean Commission to make final decision on arimoclomol MAA following negative CHMP opinion European Commission to make final decision on arimoclomol MAA following negative CHMP opinionGlobeNewswire
- Noteworthy Tuesday Option Activity: MARA, ZVRA, CRWVLooking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Marathon Digital Holdings Inc (Symbol: MARA), where a total volume of 229,493…NasdaqMARA, ZVRA, CRWV
- Zevra (ZVRA) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Zevra Reports Third Quarter 2026 Financial Results and Corporate UpdateZevra Therapeutics, Inc. reported its financial results for the third quarter ended September 30, 2026, with net revenue of $37.8 million, representing a 45% increase in total net revenue over Q3…Nasdaq
- Zevra Therapeutics, Inc. GAAP EPS of $0.26 beats by $0.11, revenue of $37.8M beats by $0.39MSeeking Alpha
- Zevra Reports Third Quarter 2026 Financial Results and Corporate Update$37.8 million net revenue for Q3 2026 , driven by $34.0 million in revenue from MIPLYFFAGlobeNewswire
- Notable Monday Option Activity: LOVE, SNOW, ZVRAAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Lovesac Co (Symbol: LOVE), where a total of 1,445 contracts have traded so far,…NasdaqLOVE, SNOW, ZVRA
- Zevra Therapeutics Announces Details for Q3 2026 Financial Results CallBOSTON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living…GlobeNewswire
- Notable Wednesday Option Activity: ZVRA, KOD, PENLooking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Zevra Therapeutics, Inc (Symbol: ZVRA), where a total volume of 8,827 contracts…NasdaqZVRA, KOD, PEN